Company profile: Rheonix
1.1 - Company Overview
Company description
- Provider of automated molecular testing solutions featuring interchangeable purification, amplification and detection, including Encompass MDx and Encompass Optimum workstations for DNA/RNA extraction and high multiplexing in food and beverage industries, and assays for SARS-CoV-2 (saliva/respiratory), Listeria PatternAlert, Beer SpoilerAlert, and Cyclospora cayetanensis in produce.
Products and services
- Encompass MDx® Workstation: A high-throughput automated molecular testing device that processes various sample types for DNA and RNA extraction and purification, supporting up to 24 samples simultaneously
- Encompass Optimum™ Workstation: An industrial-grade automated workstation engineered for high multiplexing, used for molecular testing in food and beverage industries, supporting assays for beer spoilage organisms and hop resistance genes
- Rheonix COVID-19™ MDx Assay: A clinical-grade fully automated assay that detects SARS-CoV-2 from saliva and respiratory specimens, delivering same-day results while minimizing laboratory resource demands
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rheonix
ALPCO
HQ: United States
Website
- Description: Provider of testing solutions for scientists and healthcare professionals, delivering molecular and immunodiagnostic assays across gastroenterology, allergy/infectious disease, diabetes and obesity, bone metabolism, and antibodies/antigens. Offerings include fecal calprotectin and pancreatic elastase assays, IgE allergy testing, and multiplex PCR detecting CT/NG/MG to inform research and quality of care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ALPCO company profile →
Dow Pharmaceutical Sciences
HQ: United States
Website
- Description: Provider of topical drug product development services for pharmaceutical and biotechnology clients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dow Pharmaceutical Sciences company profile →
Enlight Biosciences
HQ: United States
Website
- Description: Provider of technology platforms and software, including Entrega for enabling oral delivery of complex biological molecules and drug substances, KNODE for connecting users with experts and their content within and beyond R&D organizations, and Peerin, a Twitter application that helps professionals discover industry-specific insights by identifying and ranking high-value conversations and trends.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enlight Biosciences company profile →
Aprecia
HQ: United States
Website
- Description: Provider of precision drug delivery systems and products, including CustomRelease time-release profiles; ZipDose 3D printing for rapidly dissolving, high-dose oral tablets with taste-masking and IR/ER options; Spritam (levetiracetam); Binder Jet 3DP technology; in-cavity 3D tablet forming; capsule form & fill automation; and early-stage formulation support and rapid prototyping services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aprecia company profile →
Immunicom
HQ: United States
Website
- Description: Provider of patented Immunopheresis blood-filtering technology that removes specific blood factors to enable the immune system to fight certain cancers; the LW-02 investigational therapeutic cartridge; the EN-06 cartridge in pre-clinical development; and clinical trials at leading hospitals evaluating LW-02 for triple-negative breast cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunicom company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rheonix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rheonix
2.2 - Growth funds investing in similar companies to Rheonix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rheonix
4.2 - Public trading comparable groups for Rheonix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →